Bioxcel Therapeutics BTAI 深 滬
等待開盤 10-03 09:30:00 美东时间
2.64
+0.070
+2.72%
華盛通- 最 高2.70
- 今 開2.61
- 成交量 132.27万股
- 最 低 2.52
- 昨 收 2.57
- 總市值 5186.76万
- 52周最高 13.28
- 市盈率 靜 --
- 換手率 6.73%
- 52周最低 1.17
- 委 比 -85.52%
- 總股本 1964.68万
- 歷史最高 1144.00
- 量 比 1.09
- 振 幅 7.00%
- 歷史最低 2.52
- 每 手 1
- 風險率 2.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioXcel regains compliance with Nasdaq listing rule
BioXcel Therapeutics (NASDAQ:BTAI) has regained compliance with Nasdaq’s market value of listed securities (MVLS) requirement for continued listing on the exchange. On March 20, 2025, the company was ...
09-18 19:41
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
BioXcel Therapeutics announced it has regained compliance with Nasdaq's market value of listed securities (MVLS) requirement under Rule 5550(b)(2). The company previously fell below the $35 million threshold for 30 consecutive business days in March 2025 but received an exception after a hearing in May. Nasdaq confirmed compliance on September 17, 2025, allowing the company to continue listing on the Nasdaq Capital Market.
09-18 11:00
Bioxcel Therapeutics Files Current Report on Form 8-K
Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. Bioxcel Therapeu...
09-15 23:09
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Mizuho Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $4
Mizuho analyst Graig Suvannavejh maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target from $2 to $4.
09-12 19:57
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use.
09-11 03:08
BioXcel Therapeutics Reports Positive Phase 3 Trial Results
Bioxcel Therapeutics ( ($BTAI) ) has issued an update. On September 10, 2025, B...
09-10 18:59
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BioXcel Therapeutics' CEO, Vimal Mehta, Ph.D., will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 4:30 p.m. ET. The presentation will be available via webcast. BioXcel Therapeutics utilizes AI to develop innovative medicines in neuroscience and immuno-oncology, focusing on drug re-innovation to identify new therapeutic indications. The event webcast and additional information c...
09-04 11:00
BioXcel’s Phase 3 Trial Success for BXCL501
Bioxcel Therapeutics ( ($BTAI) ) has shared an update. On August 27, 2025, BioX...
08-27 19:28
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BioXcel Therapeutics announced that its SERENITY At-Home trial met its primary endpoint, demonstrating that BXCL501 is well-tolerated and safe for treating agitation episodes at home in patients with bipolar disorders or schizophrenia. The trial, which involved over 2,400 episodes, showed consistent benefits with repeated dosing and no serious adverse events. BioXcel plans to submit an sNDA in Q1 2026 to expand the label for at-home use, addressi...
08-27 12:00
